Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals is a promising investment opportunity due to their innovative Diffusphere technology for optimized drug delivery, promising clinical development programs in the treatment of EoE and chronic OA knee pain, and their experienced leadership team, including their new Chief Medical Officer with a focus on osteoarthritis. Market pricing reflects high probability of success, however, key questions remain around dosing and commercial rollout. Risks include clinical development, regulatory, and commercial risks, as well as potential financing and global supply chain challenges given their Canadian origins. Overall, the company shows strong potential for success in the market, but further data is needed to confirm their hypotheses.

Bears say

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company with a negative outlook primarily due to concerns about the ability to deliver their drug EP-104GI below strictures and the limited sample size of their current clinical data. Furthermore, while their ongoing Phase 2b study may help clarify their competitive profile and potential revenue opportunity, their valuation is based on a probability-weighted DCF model with only a 70% chance of success and a risk-adjusted sales estimate of $257M in 2031.

EPRX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Strong Buy based on their latest research and market trends.

According to 3 analysts, EPRX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.